PCN51 HEALTH CARE COSTS ASSOCIATED WITH ANGIOGENESIS INHIBITORS (AIS) AND MTOR INHIBITORS (MTORS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED AT US COMMUNITY ONCOLOGY CLINICS
May 1, 2010, 00:00 AM
10.1016/S1098-3015(10)72140-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)72140-9/fulltext
Section Title :
Section Order :
726
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72140-9&doi=10.1016/S1098-3015(10)72140-9